Journals / Bakırköy Tıp Dergisi / 2021 / Cilt: 17 - Sayı: 2

Inherited Metabolic Myopathies: Current Diagnosis andTreatment Approaches

Kalıtsal Metabolik Miyopatiler: Güncel Tanı ve Tedavi Yaklaşımları

Pages
108–114
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review aims to make the differential diagnosis of metabolic myopathies from other structural myopathies and present current diagnosis andtreatment approaches.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Inherited metabolic myopathies (IMMs) are a heterogeneous group of diseases characterized by inherited defects of enzymatic pathwaysinvolved in muscle cell energy metabolism.
📊
Key Findings & Data:The worldwide incidence of genetic myopathies is about 1/3500, but the incidence of IMMs isunknown.
💡
Conclusion & Impact:This review aims to make the differential diagnosis of metabolic myopathies from other structural myopathies and present current diagnosis andtreatment approaches.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Inherited metabolic myopathies (IMMs) are a heterogeneous group of diseases characterized by inherited defects of enzymatic pathwaysinvolved in muscle cell energy metabolism. The worldwide incidence of genetic myopathies is about 1/3500, but the incidence of IMMs isunknown. Although it is considered rare compared with other hereditary myopathies, the expansion of neonatal screening programs and theincrease in next-generation sequencing genetic methods for diagnosis have shown that the frequency is above the predicted rate. IMM issummarized as the name given to the group that includes defects in glycogen catabolism (glycogenolysis and glycolysis), fatty acid oxidation,Krebs cycle, or mitochondrial respiratory chain and oxidative phosphorylations. They have a broad clinical spectrum that can present symptomsof different severity at any stage of their lifetime. It differs from other myopathies in that they have unique clinical findings. Hence, it requiresspecific laboratory diagnostic methods and has specific treatments. This review aims to make the differential diagnosis of metabolic myopathies from other structural myopathies and present current diagnosis andtreatment approaches.

Özet

Kalıtsal metabolik miyopatiler (KMM), kas hücresi enerji metabolizmasında rol oynayan enzimatik yolların kalıtsal kusurları ile karakterize heterojenbir hastalık grubudur. Dünya çapında genetik miyopatilerin insidansı yaklaşık 1/3500, ancak gerçek KMM insidansı bilinmemektedir. Yenidoğantarama programlarının yaygınlaşması ve yeni nesil dizileme genetik yöntemlerinin artması ile diğer genetik miyopatilerle kıyaslandığında nadirolduğu düşünülse de, sıklığın tahmin edilen oranın üzerinde olduğu tahmin edilmektedir. KMM, glikojen katabolizması (glikojenoliz ve glikoliz),yağ asidi oksidasyonu, Krebs döngüsü veya mitokondriyal solunum zinciri ve oksidatif fosforilasyondaki kusurları içeren gruba verilen isim olaraközetlenmektedir. Yaşamın herhangi bir anında farklı şiddette semptomlarla ortaya çıkabilen geniş bir klinik yelpazeye sahiptirler. Kendine özgünklinik bulgulara sahip olmaları, spesifik laboratuvar tanı yöntemlerine ihtiyaç duymaları ve özgün tedavi şekilleri olmasıyla diğer miyopatilerdenfarklılık gösterirler. Bu derlemenin amacı, metabolik miyopatilerin diğer yapısal miyopatilerden ayırıcı tanısını yapmak ve güncel tanı ve tedavi yaklaşımlarınısunmaktır.

🔖

Cite This Article

ERSOY, M. (2022). Inherited Metabolic Myopathies: Current Diagnosis andTreatment Approaches. Bakırköy Tıp Dergisi, Cilt: 17 - Sayı: 2, 108–114. https://ajindex.com/articles/459987

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Koo P, Sethi JM. Metabolic Myopathies and the Respiratory System. Clin Chest Med 2018;39:401-10
  2. Tarnopolsky MA. Metabolic Myopathies. Continuum (Minneap Minn) 2016;22:1829-51
  3. Finsterer J. An update on diagnosis and therapy of metabolic myopathies. Expert Rev Neurother 2018;18:933-43. 4. van Loon LJ, Greenhaff PL, Constantin-Teodosiu D, Saris WH, Wagenmakers AJ. The effects of increasing exercise intensity on muscle fuel utilisation in humans. J Physiol 2001;536:295-304
  4. Perry CG, Kane DA, Herbst EA, Mukai K, Lark DS, Wright DC, et al. Mitochondrial creatine kinase activity and phosphate shuttling are acutely regulated by exercise in human skeletal muscle. J Physiol 2012;590:5475-86. 6. Ørtenblad N, Westerblad H, Nielsen J. Muscle glycogen stores and fatigue. J Physiol 2013;591:4405-13. 7. van Adel BA, Tarnopolsky MA. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009;10:97-121
  5. DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001;24:984-99
  6. Hedberg-Oldfors C, Mensch A, Visuttijai K, Stoltenburg G, Stoevesandt D, Kraya T, et al. Polyglucosan myopathy and functional characterization of a novel GYG1 mutation. Acta Neurol Scand 2018;137:308-15
  7. Preisler N, Haller RG, Vissing J. Exercise in muscle glycogen storage diseases. J Inherit Metab Dis 2015;38:551-63
  8. Tang H, Feuchtbaum L, Sciortino S, Matteson J, Mathur D, Bishop T, et al. The First Year Experience of Newborn Screening for Pompe Disease in California. Int J Neonatal Screen 2020;6:9. 12. van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol 2017;24:768-31
  9. Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012;259:952-8
  10. Angelini C, Semplicini C, Ravaglia S, Moggio M, Comi GP, Musumeci O, et al. New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 2012;45:831-4
  11. Nascimbeni AC, Fanin M, Tasca E, Angelini C. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency. Neurology 2008;70:617-26
  12. Finsterer J. An update on diagnosis and therapy of metabolic myopathies. Expert Rev Neurother 20